title: Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1.
abstract: The improved prognosis of HIV-infection that has occurred since the introduction of highly active antiretroviral therapy (HAART) has resulted in renewed emphasis being placed on co-morbidities associated with HIV-infection, and chronic viral hepatitis in particular. Hepatitis B virus (HBV) infection is an important infection in HIV-1 infected individuals because of the influence of HIV-1 co-infection on the natural history of HBV infection. Antiviral therapies with activity against both viruses have enabled targeted therapy in co-infected individuals, however, optimism regarding improved prognosis has been tempered by the development of antiviral resistant HBV. Emerging new classes of HBV therapies herald the possibility of combination HBV therapy.
authors.affiliation: Victorian Infectious Diseases Reference Laboratory, North Melbourne, Melbourne, Vic, Australia.
authors.forename: Louise
authors.initials: L
authors.lastname: Cooley
authors.forename: Joseph
authors.initials: J
authors.lastname: Sasadeusz
mesh_terms: D000465:Algorithms; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D015497:HIV-1; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D009154:Mutation; D011994:Recombinant Proteins
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins